Gain Therapeutics Inc.(GANX)

$1.91—

Chart

Gain Therapeutics Inc.(GANX)

NASDAQ

$1.91—

Chart Studio

GANX(GANX)

GANX

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.14

Aug 11, 2026 · Reports before open

Revenue Estimate

$33,333

FY2030E EPS$1.64

Analyst Sentiment

Wall St. Consensus

Buy

8 analysts·Limited coverage

Score

7 Buy (88%)1 Hold (13%)0 Sell (-1%)

Rating Breakdown

Strong Buy

00%

Buy

788%

Hold

113%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$4.00

+109.4%

Consensus

$8.00

+318.8%

Bull

$10.00

+423.6%

12-Month Target Range8 analysts

$4.00$8.00$10.00

Current $1.91Consensus

Current Price

$1.91

Upside to Consensus

$6.09

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+350.00%

EPS—

FY2028

Rev+44474.53%

EPS—

FY2029

Rev-52.07%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$50,000	$225,000	$100M	$48M	$135M
Low	$50,000	$225,000	$100M	$48M	$135M
High	$50,000	$225,000	$100M	$48M	$135M
EBITDA Avg	$-9,999	$-44,999	$-20M	$-10M	$-27M
Low	$-9,999	$-44,999	$-20M	$-10M	$-27M
High	$-9,999	$-44,999	$-20M	$-10M	$-27M
EBIT Avg	$-9,999	$-44,999	$-20M	$-10M	$-27M
Low	$-9,999	$-44,999	$-20M	$-10M	$-27M
High	$-9,999	$-44,999	$-20M	$-10M	$-27M
Net Income Avg	$-19M	$-25M	$-25M	$-494,525	$54M
Low	$-20M	$-30M	$-31M	$-494,525	$54M
High	$-17M	$-20M	$-19M	$-494,525	$54M
EPS Avg	$-0.56	$-0.74	$-0.76	$-0.01	$1.64
Low	$-0.60	$-0.92	$-0.94	$-0.01	$1.64
High	$-0.53	$-0.60	$-0.58	$-0.01	$1.64
Analysts (Rev / EPS)	4 / 4	5 / 3	2 / 2	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$33,333	$33,333	—	—	—	—
Low	$33,333	$33,333	—	—	—	—
High	$33,333	$33,333	—	—	—	—
EBITDA Avg	$-6,666	$-6,666	—	—	—	—
Low	$-6,666	$-6,666	—	—	—	—
High	$-6,666	$-6,666	—	—	—	—
EBIT Avg	$-6,666	$-6,666	—	—	—	—
Low	$-6,666	$-6,666	—	—	—	—
High	$-6,666	$-6,666	—	—	—	—
Net Income Avg	$-6M	$-6M	$-6M	$-6M	$-10M	$-10M
Low	$-7M	$-6M	$-6M	$-6M	$-10M	$-10M
High	$-6M	$-6M	$-6M	$-6M	$-10M	$-10M
EPS Avg	$-0.14	$-0.14	$-0.13	$-0.14	$-0.23	$-0.23
Low	$-0.15	$-0.14	$-0.13	$-0.14	$-0.23	$-0.23
High	$-0.13	$-0.14	$-0.13	$-0.14	$-0.23	$-0.23
Analysts (Rev / EPS)	2 / 3	3 / 1	— / 1	— / 1	— / 1	— / 1

Earnings Surprises

Recent Analyst Actions

Dec 19, 2025Roth Capital

Gain Therapeutics price target raised to $10 from $6 at Roth Capital

Target:$10.00

+259.0%from $2.79

Dec 1, 2025H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Target:$8.00

+128.6%from $3.50

Oct 7, 2025Maxim Group

Gain Therapeutics price target raised to $7 from $5 at Maxim

Target:$7.00

+255.3%from $1.97

Dec 9, 2022Chardan Capital

Chardan Capital Initiates Coverage On Gain Therapeutics with Buy Rating, Announces Price Target of $4

Target:$4.00

+27.0%from $3.15

Nov 13, 2022BTIG

Gain Therapeutics price target lowered to $10 from $30 at BTIG

Target:$10.00

+211.5%from $3.21

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance